Rubric Capital Management (New York)’s Tarsus Pharmaceuticals TARS Stock Holding History

Rubric Capital Management (New York)’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-221,488	Closed	-$2.78M	–	73
2023 Q1	$2.78M	Sell	221,488 -63,244	-22%	-$925K	0.07%	65
2022 Q4	$4.17M	Hold	284,732	–	–	0.18%	75
2022 Q3	$4.88M	Buy	284,732 +82,084	+41%	+$1.3M	0.25%	62
2022 Q2	$2.96M	Buy	+202,648	New	+$3.04M	0.16%	73

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rubric Capital Management (New York)'s TARS Position: Q2 2023 in Review

Rubric Capital Management (New York) sold out of Tarsus Pharmaceuticals (TARS) in Q2 2023, closing a stake of 221,488 shares — an estimated $2.78M sold.

Rubric Capital Management (New York) first reported a position in TARS in Q2 2022 and held it in 4 quarters. The position peaked at $4.88M in Q3 2022. 92 funds tracked by Wall St. Rank hold TARS as of Q2 2023.

Rubric Capital Management (New York) reported no remaining Tarsus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Rubric Capital Management (New York) sold 221,488 Tarsus Pharmaceuticals shares in Q2 2023, an estimated $2.78M.
Rubric Capital Management (New York) first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 4 quarters.
Rubric Capital Management (New York)'s Tarsus Pharmaceuticals position peaked at $4.88M in Q3 2022.
92 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2023, filed 11 Aug 2023.